ClassID:

21562

A61K51/0485 - CPC Classification

Classification description:

Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a NS, NS, NS, N chelating group Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal

Recent Application in this class:
#1
20250255991
2025-08-14

SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER

#2
20250235565
2025-07-24

IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)

#3
20250195701
2025-06-19

Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies

#4
20250186628
2025-06-12

IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)

#5
20250064995
2025-02-27

PSMA TARGETED COMPOUNDS AND USES THEREOF

#6
20250009913
2025-01-09

COMPOUNDS FOR USE IN NON-COVALENT SCAFFOLD AND METHODS RELATED THERETO

#7
20240358866
2024-10-31

NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING

#8
20240293584
2024-09-05

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)

#9
20240285816
2024-08-29

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING

#10
20230414795
2023-12-28

PSMA targeted compounds and uses thereof

#11
20230405157
2023-12-21

MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF

#12
20230398239
2023-12-14

Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies

#13
20230364274
2023-11-16

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)

#14
20230348535
2023-11-02

RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER

#15
20230052140
2023-02-16

IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF

#16
20220162241
2022-05-26

Chelated PSMA Inhibitors

#17
20220025185
2022-01-27

SPECIFICALLY GLYCO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY

#18
20220001012
2022-01-06

NOVEL COMPOUNDS AND USES OF SAME FOR NEAR-INFRARED CHERENKOV LUMINESCENCE IMAGING AND/OR FOR DEEP TISSUE TREATMENT BY CHERENKOV DYNAMIC PHOTOTHERAPY

#19
20210402013
2021-12-30

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING

#20
20200345846
2020-11-05

CORROLE COMPOSITIONS

#21
20200339625
2020-10-29

NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER

#22
20200330625
2020-10-22

Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer

#23
20200330624
2020-10-22

IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)

#24
20200157099
2020-05-21

3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents

#25
20190336621
2019-11-07

Radioactive compound for diagnosis of malignant melanoma and use thereof

#26
20190309000
2019-10-10

Chelated PSMA inhibitors

#27
20190282715
2019-09-19

FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING

#28
20190083662
2019-03-21

IGF-1R monoclonal antibodies and uses thereof

#29
20180344883
2018-12-06

3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents

#30
20180126012
2018-05-10

Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies

#31
20170239377
2017-08-24

Molecular probes for multimodality imaging and tracking of stem cells

#32
20150374859
2015-12-31

Imaging compounds for tracking histone deacetylase inhibitor and synthesis method thereof

#33
20150297717
2015-10-22

Pharmaceutical formulations

#34
20150157712
2015-06-11

Cancer treatment

#35
20140341806
2014-11-20

Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma

#36
20140011985
2014-01-09

Targeted Cancer Therapy Conjugates Using Porphyrins and Porphyrin-like Molecules and Various Cytotoxic Agents

#37
20130216478
2013-08-22

Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma

#38
20130004419
2013-01-03

Carbonylporphyrins and uses thereof

#39
20120070372
2012-03-22

Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma

#40
20110064658
2011-03-17

RGD-(bacterio)chlorophyll conjugates for photodynamic therapy and Imaging of Necrotic tumors

#41
20100184970
2010-07-22

Porphyrin-based compounds for tumor imaging and photodynamic therapy

#42
20080279781
2008-11-13

Glycosylated Carboranylporphyrins and Uses Thereof

#43
20080233047
2008-09-25

Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof

#44
20080131376
2008-06-05

Carboranylporphyrins and uses thereof

#45
20070048216
2007-03-01

Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma

#46
20070043289
2007-02-22

Method and Apparatus Including Use of Metalloporphyrins for Subsequent Optimization of Radiosurgery and Radiotherapy

#47
20060204437
2006-09-14

Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and NSconjugates for MR contrast media and radiopharmaceuticals

#48
20060198783
2006-09-07

Porphyrin-based compounds for tumor imaging and photodynamic therapy

#49
20050287073
2005-12-29

Carboranylporphyrins and uses thereof

#50
20050226810
2005-10-13

Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis

#51
20050004010
2005-01-06

Cobalamin conjugates useful as imaging agents and as antitumor agents